Human medicines European public assessment report (EPAR): Lucentis, ranibizumab, Wet Macular Degeneration,Macular Edema,Myopia, Degenerative,Diabetes Complications, Date of authorisation: 21/01/2007, Revision: 30, Status: Authorised

2018 ◽  
Author(s):  
Keyword(s):  
Macular Degeneration ◽  
Macular Edema ◽  
Diabetes Complications ◽  
Assessment Report ◽  
European Public ◽  
European Public Assessment Report
Sign in / Sign up

Export Citation Format

Share Document